Form 8-K

8-K — Hemab Therapeutics Holdings, Inc.

Accession: 0001193125-26-343421

Filed: 2026-08-11

Period: 2026-08-11

CIK: 0002114044

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — d180684d8k.htm (Primary)

EX-99.1 (d180684dex991.htm)

GRAPHIC (g180684g0811020433122.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d180684d8k.htm · Sequence: 1

8-K

false 0002114044 0002114044 2026-08-11 2026-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2026

Hemab Therapeutics Holdings, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-43250

41-4241952

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

101 Main Street, Suite 1220

Cambridge, Massachusetts

02142

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 553-3952

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

symbol(s)

Name of each exchange

on which registered

Common stock, $0.0001 par value per share

COAG

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

On August 11, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1

Press Release issued by Hemab Therapeutics Holdings, Inc. on August 11, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEMAB THERAPEUTICS HOLDINGS, INC.

Date: August 11, 2026

By:

/s/ Benny Sørensen, M.D., Ph.D.

Name: Benny Sørensen, M.D., Ph.D.

Title: President and Chief Executive Officer

EX-99.1

Filename: d180684dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis

and Haemostasis (ISTH) 2026 Congress in Paris, France

New clinical data on HMB-002

demonstrated ≥ 2.4-fold increase in Von Willebrand Factor (VWF) and Factor VIII (FVIII), stronger than anticipated proof of mechanism, and encouraging preliminary clinical observations in

Von Willebrand Disease (VWD)

Unveiled HMB-003, a novel

non-hormonal, peptide-based plasmin inhibitor designed to reduce bleeding across multiple settings, beginning with heavy menstrual bleeding indication

Long-term extension (LTE) data for sutacimig showed sustained favorable results in Glanzmann thrombasthenia (GT), and FDA endorsed the

sutacimig clinical data package as sufficient to proceed to a Phase 3 pivotal trial in GT; Phase 3 initiation planned 2H 2026

CAMBRIDGE, MA,

USA & COPENHAGEN, Denmark — August 11, 2026 — Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation

disorders to sustain life and human resilience, today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.

“This was a very productive quarter for Hemab with continued execution across our pipeline,” said Benny Sørensen, MD, PhD, CEO of Hemab.

“We had a significant presence at ISTH 2026, presenting data from all our programs. The strong interest we saw in that data underscores both the significant unmet need in bleeding disorders and the potential for our clinical and preclinical

pipeline to redefine the standard of care in this space. We are particularly pleased to announce a new program, HMB-003, where we are addressing heavy menstrual bleeding, an indication that affects millions of

women globally. HMB-003 is another example of how Hemab is developing treatments that could redefine care across high-unmet-need bleeding disorders. We look forward to providing additional updates on our

programs later this year.”

Corporate Highlights

In July, the Company presented at the ISTH 2026 Congress in Paris, France, delivering nine presentations across three clinical and preclinical programs. All

ISTH presentations are available on the Company’s corporate website (here).

Recent Business Highlights and Anticipated Milestones

Sutacimig: Sutacimig is a bispecific antibody in clinical development for two indications: GT and Factor VII deficiency (FVIID). Sutacimig has

received Fast Track, Orphan Drug, and Breakthrough Therapy Designations from the U.S. Food and Drug Administration (FDA) for the treatment of GT. In Europe, the European Medicines Agency (EMA) has granted sutacimig Orphan Medicinal Product

designation for the treatment of GT and access to the Priority Medicines (PRIME) scheme. Sutacimig has also received the Innovative Licensing and Access Pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency

(MHRA).

Glanzmann Thrombasthenia: GT is a congenital, severe, lifelong bleeding disorder caused by defects in

platelet aggregation, with substantial geographic variation in prevalence, from approximately 1 in 100,000 individuals in high-prevalence regions such as the Gulf Cooperation Council (GCC) countries to between 1 in 350,000 and 1 in 600,000 in the

United States. There are currently no approved prophylactic treatment options for GT; management is limited to platelet transfusions, antifibrinolytics, recombinant Factor VIIa, and bone marrow transplantation.

•

In July, the Company presented Phase 2 LTE data for sutacimig at ISTH 2026. The data demonstrated clinically

meaningful and sustained bleed reduction in 34 participants at a median timepoint of 6.9 months and up to 15.9 months of exposure. Ninety-two percent (92%) of participants who had bled during the run-in experienced reductions in treated bleed rates on sutacimig, and the mean high-intensity annualized treated bleed event rate (ATBR) was reduced by 62% over the treatment and extension period; in the low-dose weekly regimen cohort, mean ATBR was reduced by approximately 84%.

•

Adverse events were predominantly mild to moderate, with no Grade 3 or higher related adverse events. Three

participants experienced Grade 2 thromboembolic events; these occurred in participants assigned to dose cohorts associated with higher exposure and/or with multiple concurrent risk factors, and all were managed with routine anticoagulation and were

resolved or resolving at the data cut. The Phase 3 dose and regimen were selected to optimize bleed rate reduction while avoiding the high peak exposures associated with thromboembolic events observed in the Phase 1/2 trial.

•

The FDA has endorsed the Company’s clinical data package as sufficient to proceed to a Phase 3 pivotal

trial in GT with a dose of 0.2 mg/kg once weekly. The Company plans to initiate the Phase 3 trial in the second half of 2026.

Factor

VII Deficiency: FVIID is a congenital severe bleeding disorder, with prevalence of moderate and severe forms estimated at approximately 1 in 500,000 globally and characterized by impaired blood clotting and increased bleeding risk.

•

The Company is conducting an ongoing Phase 2 clinical trial of sutacimig for FVIID. New preclinical data for

sutacimig presented at ISTH 2026 demonstrated restoration of thrombin generation under disease-mimicking conditions, with confirmed binding across 22 of 25 tested

severe-to-moderate FVIID variants (88%), supporting broad patient applicability for the ongoing Phase 2 trial.

•

The Company expects to report data from the ongoing Phase 2 trial in late 2026 or early 2027.

HMB-002—Von Willebrand Disease: HMB-002 is

a novel monovalent antibody designed for subcutaneous prophylactic treatment of VWD, the most common inherited bleeding disorder, with approximately 140,000 patients diagnosed across all severity levels in the United States, of whom more than an

estimated 50,000 require treatment for bleeding events.

•

In July, the Company presented new

first-in-human data at ISTH 2026 supporting HMB-002 as a non-replacement approach to

treating VWD. Data from the ongoing VELORA Pioneer Phase 1/2 trial demonstrated proof of mechanism, a ≥2.4-fold peak increase in VWF and FVIII, normalization of peak thrombin generation and APTT, and a

durability profile supporting potential monthly subcutaneous dosing. The single ascending dose portion of the study was not designed to measure efficacy, and the following preliminary clinical observations are descriptive in nature. Across the

single ascending dose cohorts, 8 of 9 evaluable patients had zero treated bleeds in the 28 days following HMB-002 dosing, with a mean ATBR of 1.6, compared with a baseline mean ATBR of 20.1 prior to treatment.

•

The Company expects to report additional data from the trial in late 2026 or early 2027.

HMB-003—Novel Antifibrinolytic Program: HMB-003 is a novel

fatty-acid-conjugated peptide antifibrinolytic, designed to stabilize clots and reduce bleeding across multiple settings, beginning in heavy menstrual bleeding, an indication affecting one in three

reproductive-age women, over 23 million women, in the U.S.

•

In July, the Company unveiled HMB-003, a long-acting subcutaneous plasmin

inhibitor with the potential for cycle-matched dosing, initially being developed in heavy menstrual bleeding. HMB-003 is also being developed to address bleeding in additional high-unmet-need conditions,

including hereditary hemorrhagic telangiectasia and peri-operative bleeding management.

•

Preclinical data presented at ISTH 2026 demonstrated potent and selective plasmin inhibition, with HMB-003 directly inhibiting plasmin at its active site and blocking fibrinolysis across both tPA- and uPA-driven pathways, while showing no effect on thrombin generation,

platelet function, or coagulation. In a preclinical model, HMB-003 achieved rapid peak plasma levels within hours and sustained antifibrinolytic activity for approximately one week, supporting the potential

for cycle-matched dosing in people experiencing heavy menstrual bleeding.

•

The Company plans to initiate

first-in-human studies in the second half of 2026 with initial clinical data mid-2027.

Second Quarter 2026 Financial Results

•

Cash Position and Cash Runway: Cash, cash equivalents, and marketable securities totaled

$457.5 million as of June 30, 2026, compared to $163.5 million as of March 31, 2026. The increase primarily reflects net proceeds of $317.2 million from the Company’s initial public offering completed in May 2026,

partially offset by cash used in operating activities. The Company believes its current cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into 2029.

•

Research and Development Expenses: Research and development expenses were $20.3 million for the three

months ended June 30, 2026, compared to $12.9 million for the three months ended June 30, 2025. The increase was due to costs related to the advancement of clinical programs in addition to increases in equity-based compensation

and personnel-related expenses related to company growth to support the advancement of our programs.

•

General and Administrative Expenses: General and administrative expenses were $5.7 million for the

three months ended June 30, 2026, compared to $3.2 million for the three months ended June 30, 2025, due to equity-based compensation and other costs associated with operating as a public company.

•

Net Loss: Net loss was $24.2 million, or $0.80 per share, for the three months ended June 30,

2026, compared to a net loss of $12.2 million, or $12.91 per share, for the three months ended June 30, 2025. The decrease in net loss per share primarily reflects the increase in weighted-average shares outstanding during the three months

ended June 30, 2026 following the Company’s initial public offering and the subsequent conversion of preferred stock into common stock in May 2026.

Conference Call Information: Beginning with its third quarter 2026 financial results, Hemab Therapeutics plans to host quarterly conference calls to

discuss its financial results and provide business updates. Details regarding the date, time and webcast registration for the third quarter 2026 call will be announced in a subsequent press release.

About Glanzmann Thrombasthenia

Glanzmann

thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international natural history study (Glanzmann’s 360) revealed the substantial burden of this disease: 88%

of the 117 participants reported at least one bleed in the previous week with 65% requiring a bleed-related hospital visit in the prior six months. These bleeding episodes significantly impacted patients’ mental health and quality of life,

with over 80% having missed work or school, over 50% facing limitations in attending social events, and over 50% experiencing restrictions in travel. To date, there are no approved prophylactic treatment options for GT. About Factor VII

Deficiency Factor VII deficiency (FVIID) is a congenital severe bleeding disorder characterized by reduced levels of Factor VII, a naturally circulating blood coagulation protein. Patients with clinically severe FVIID suffer from recurrent,

unpredictable, life-threatening or potentially disabling bleeding at critical sites, such as in the central nervous system, gastrointestinal tract and intra-articular locations, as well as recurrent mucocutaneous bleeds of the nose and gums with

additional risks for female patients, consisting of heavy menstrual bleeding and potentially life-threatening post-partum hemorrhage.

About Sutacimig

(formerly HMB-001)

Sutacimig is a subcutaneously administered bispecific antibody that is designed to

bind and stabilize endogenous Factor VIIa with one antibody arm and bind to TLT-1 on activated platelets with the other arm. This mechanism is designed to allow for the accumulation of endogenous Factor VIIa

in the body and recruitment of Factor VIIa directly to the surface of the activated platelets, where it amplifies thrombin generation at the platelet surface. Sutacimig is designed to be a first-in-class prophylactic treatment for Glanzmann thrombasthenia (GT) with the potential to treat other debilitating bleeding disorders. The U.S. Food and Drug Administration has granted Fast Track

Designation, Orphan Drug Designation, and Breakthrough Therapy Designation to sutacimig for the treatment of GT, and the UK Medicines and Healthcare products Regulatory Agency has awarded sutacimig designation under the Innovative Licensing and

Access Pathway (ILAP); it has been designated as an orphan medicinal product in the European Union for the treatment of GT, and the European Medicines Agency (EMA) has granted sutacimig access to the Priority Medicines (PRIME) scheme. For more

information, please visit clinicaltrials.gov (NCT06211634).

About Von Willebrand Disease

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand

Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening

hemorrhages. Chronic blood loss frequently leads to iron deficiency anemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options

for VWD primarily focus on managing symptoms rather than addressing the underlying biology of the disease.

About

HMB-002

HMB-002 is a monovalent human antibody being developed

as the first-in-class subcutaneous prophylactic treatment for Von Willebrand Disease targeting the underlying cause of the disease, a condition driven by a deficiency or

defect in Von Willebrand Factor (VWF), a key regulator of hemostasis. By specifically targeting the C-terminal CK domain of VWF, which is distinct from regions critical to its essential interactions, HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more

information, please visit clinicaltrials.gov (NCT06610201 and NCT06754852). About HMB-003 HMB-003 is a subcutaneously administered peptide-based plasmin inhibitor

with a durable half-life — a proven therapeutic target in coagulation medicine — being developed as a novel antifibrinolytic designed to reduce bleeding across multiple settings. Engineered to directly inhibit plasmin at its active site,

HMB-003 blocks fibrinolysis independently of the plasminogen activation pathway. HMB-003 is optimized to provide sustained bleed protection across multiple

high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management.

About Hemab Therapeutics

Hemab Therapeutics Holdings,

Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative

therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including

sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a

monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in preclinical development for multiple

high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management.

Learn

more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical

facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, the anticipated timelines for reporting data from Hemab’s clinical trials, the

anticipated timelines for initiating a Phase 3 clinical trial of sutacimig and further development of HMB-002 and HMB-003, the clinical potential of sutacimig, HMB-002 and HMB-003, Hemab’s plans to expand its

pipeline, and the sufficiency of Hemab’s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act

of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,”

“ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify

forward-looking statements, although not all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place

undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including:

uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical

studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials;

whether Hemab’s cash resources will be sufficient to fund Hemab’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the

Securities and Exchange Commission (SEC), including Hemab’s most recent Form 10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press

release represent Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some

point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release.

Media:

Deerfield Group

Peg Rusconi

peg.rusconi@deerfieldgroup.com

Investors:

Hemab Therapeutics

Mads Behrndt

investors@hemab.com

Hemab Therapeutics Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Operating expenses

Research and development

20,336

12,874

39,797

26,975

General and administrative

5,743

3,183

9,894

5,642

Total operating expenses

26,079

16,057

49,691

32,617

Loss from operations

(26,079

)

(16,057

)

(49,691

)

(32,617

)

Other income (expense), net

Interest income

2,858

335

4,077

808

Other (expense) income, net

(832

)

3,517

(1,114

)

4,108

Total other income, net

2,026

3,852

2,963

4,916

Loss before income tax expense

(24,053

)

(12,205

)

(46,728

)

(27,701

)

Income tax (expense) benefit

(97

)

(109

)

186

Net loss

(24,150

)

(12,209

)

(46,837

)

(27,515

)

Net loss per share, basic and diluted

(0.80

)

(12.91

)

(3.00

)

(29.09

)

Weighted average shares outstanding, basic and diluted

30,111,338

946,000

15,609,236

946,000

Other comprehensive loss

Net loss

(24,150

)

(12,209

)

(46,837

)

(27,515

)

Net unrealized (loss) gain on

available-for-sale debt securities

(2,309

)

(609

)

(2,923

)

365

Total comprehensive loss

(26,459

)

(12,818

)

(49,760

)

(27,150

)

Hemab Therapeutics Holdings, Inc.

Selected Consolidated Balance Sheets Data

(In thousands)

(Unaudited)

June 30,

2026

December 31,

2025

Assets

Cash and cash equivalents

237,366

87,974

Marketable securities

220,094

97,511

Prepaid expenses and other current assets

6,538

7,066

Property and equipment, net

596

609

Operating

right-of-use assets

901

1,092

Other non-current assets

2,286

531

Total assets

467,781

194,783

Liabilities and stockholders’ equity (deficit)

Accounts payable

6,232

5,734

Operating lease liabilities

460

647

Operating lease liabilities, net of current portion

566

573

Accrued expenses and other current liabilities

6,252

4,296

Total liabilities

13,510

11,250

Total convertible preferred stock and convertible preference shares

—

360,168

Total stockholders’ equity (deficit)

454,271

(176,635

)

Hemab Therapeutics Holdings, Inc.

Selected Consolidated Statements of Cash Flows Data

(In thousands)

(Unaudited)

Six Months Ended June 30,

2026

2025

Change

Net cash used in operating activities

(44,221

)

(28,366

)

(15,855

)

Net cash (used in) provided by investing activities

(123,284

)

15,508

(138,792

)

Net cash provided by (used in) financing activities

317,119

(59

)

317,178

Effect of foreign exchange rate changes on cash and cash equivalents

(222

)

—

(222

)

Net increase (decrease) in cash and cash equivalents

149,392

(12,917

)

162,309

GRAPHIC

Filename: g180684g0811020433122.jpg · Sequence: 6

Binary file (3627 bytes)

Download g180684g0811020433122.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information

Aug. 11, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0002114044

Document Type

8-K

Document Period End Date

Aug. 11, 2026

Entity Registrant Name

Hemab Therapeutics Holdings, Inc.

Entity Incorporation State Country Code

Entity File Number

001-43250

Entity Tax Identification Number

41-4241952

Entity Address, Address Line One

101 Main Street

Entity Address, Address Line Two

Suite 1220

Entity Address, City or Town

Cambridge

Entity Address, State or Province

Entity Address, Postal Zip Code

02142

City Area Code

(617)

Local Phone Number

553-3952

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common stock, $0.0001 par value per share

Trading Symbol

COAG

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration